

- 1 Fisher J.P., Adamson D.C. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. *Biomedicines*. 2021 Mar, 22, vol. 9(3), p. 324, doi: 10.3390/biomedicines 9030324. PMID: 33810154; PMCID: PMC8004675
- 2 Yoshida M., Yamaguchi S., Ishi Y. et al. Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas. *No Shinkei Geka*. 2015 Jul, vol. 43(7), p. 603-610.
- 3 Hau, P. et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent highgrade glioma. *Cancer*, 2004, vol. 100 (1), p. 1199-1207
- 4 Lesniak M.S., Upadhyay U., Goodwin R., Tyler B., Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. *Anticancer Res*. 2005 Nov-Dec, vol. 25(6B), p. 3825-3831